In the first quarter of 2025, the Zelenograd production site of Binnopharm Group increased its output of medicinal products for export by almost three times compared to the same period in 2024.
Vamotinib is about to be registered and put into civil circulation by Pharmasyntez, a Russian pharmaceutical company that aims to provide Russian patients with access to new and innovative medications.
The quarterly review provides information on the inspection of manufacturers of veterinary medicines for compliance with the requirements of the Good Manufacturing Practice (GMP)...
Binnopharm Group, one of Russia’s leading pharmaceutical companies, announced a successful placement of its second bond issue in the current year. The amount of...
The children's vaccine Encevir Neo for the prevention of tick-borne encephalitis, developed by SPA Microgen (part of the Nacimbio holding company of Rostec State...
On February 25, a working meeting of experts was held at the Russian Union of Industrialists and Entrepreneurs (RSPP) to develop proposals for amending...